XtalPi Holdings Limited (XTALPI) disclosed the award of 34.98 million share options and 8.68 million restricted share units (RSUs) to four executive directors on 2 July 2026 under its 2026 Share Scheme.

Key details • Beneficiaries: Executive Directors Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan. • Share options: 34.98 million units—equal to 0.81% of the company’s 4.30 billion issued shares. – Exercise price: HK$7.48, matching the closing price on the grant date. – Term: 10 years. – Vesting: 25% annually over four years, subject to individual and group performance metrics and a claw-back mechanism. • RSUs: 8.68 million units—0.20% of shares outstanding. – No purchase price. – Same four-year, 25%-per-year vesting schedule, with identical performance hurdles and claw-back terms.

Director-level allocation • Dr. Wen Shuhao: 17.65 million options (0.41% of shares) and 4.30 million RSUs (0.10%). • Dr. Ma Jian: 9.71 million options (0.23%) and 2.43 million RSUs (0.06%). • Dr. Lai Lipeng: 7.06 million options (0.16%) and 1.77 million RSUs (0.04%). • Dr. Jiang Yide Alan: 0.56 million options (0.01%) and 0.19 million RSUs (0.004%).

Governance and regulatory compliance • The awards were approved by all independent non-executive directors; each grantee abstained from voting on their own grants. • The grants comply with Listing Rules 17.04(1), 17.04(2), 17.04(3) and 17.03D(1); no shareholder approval is required. • Following this issuance, 137.86 million shares remain available for future grants under the company’s share schemes.

Strategic rationale The company states that the incentive awards aim to recognise past contributions and motivate senior management to drive future growth, with performance-linked vesting and claw-back provisions aligning executives’ interests with long-term shareholder value.